How do the Australian guidelines for lipid‐lowering drugs perform in practice? Cardiovascular disease risk in the AusDiab Study, 1999–2000

Objective: To determine how well the current Pharmaceutical Benefits Scheme (PBS) eligibility criteria for subsidy of lipid‐lowering drugs compare with current national guidelines for determining the population at high risk of developing cardiovascular disease (CVD). Design and participants: Analyse...

Full description

Saved in:
Bibliographic Details
Published in:Medical journal of Australia 2008-09, Vol.189 (6), p.319-322
Main Authors: Chen, Lei, Rogers, Sophie L, Colagiuri, Stephen, Cadilhac, Dominique A, Mathew, Timothy H, Boyden, Andrew N, Peeters, Anna, Magliano, Dianna J, Shaw, Jonathan E, Zimmet, Paul Z, Tonkin, Andrew M
Format: Article
Language:English
Subjects:
Adult
Aged
Angina pectoris
Australia
Biological and medical sciences
Blood pressure
Cardiovascular disease
Cardiovascular diseases
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Cholesterol
Cross-Sectional Studies
Diabetes
Diabetes Complications - complications
Diabetes. Impaired glucose tolerance
Drugs
Electrocardiography
Endocrine pancreas. Apud cells (diseases)
Endocrinopathies
Etiopathogenesis. Screening. Investigations. Target tissue resistance
Female
General aspects
Guideline Adherence
Heart failure
High density lipoprotein
Humans
Hypolipidemic Agents - therapeutic use
Lipids
Male
Medical sciences
Metabolic syndrome
Metabolic Syndrome - complications
Middle Aged
Native peoples
Pharmaceuticals
Population
Practice Guidelines as Topic
Practice Patterns, Physicians
Risk Assessment
Risk factors
Stroke
Subsidies
Triglycerides
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: To determine how well the current Pharmaceutical Benefits Scheme (PBS) eligibility criteria for subsidy of lipid‐lowering drugs compare with current national guidelines for determining the population at high risk of developing cardiovascular disease (CVD). Design and participants: Analyses of the population‐based, cross‐sectional Australian Diabetes, Obesity and Lifestyle (AusDiab) study, conducted in 1999–2000. The 1991 Framingham risk prediction equation was used to compute 5‐year risk of developing first‐time CVD in 8286 participants aged 30–74 years with neither CVD nor diabetes. Based on the National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand guidelines, people with either 5‐year CVD risk ≥ 15% or with 5‐year CVD risk of 10%–
ISSN:0025-729X
1326-5377
DOI:10.5694/j.1326-5377.2008.tb02049.x